About 29 results found for searched term "CDK2" (0.056 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M13422 | Beloranib | Others |
| ZGN-440；CDK-732 | ||
| Beloranib is a methionine aminopeptidase 2 (METAP2) inhibitor. It's an experimental compound candidate for obesity research. | ||
| M13601 | CDK9-IN-2 | CDK |
| CDK9-IN-2 is a special cyclin-dependent kinase 9 (CDK9) inhibitor, with IC50s of 5 nM and 7 nM in H929 multiple myeloma(MM) cell line (72 hours) and A2058 skin cell line (72 hours), respectively. | ||
| M22026 | CDK2 | Others |
| CDK2 | ||
| M29110 | CDK12-IN-E9 | CDK |
| CDK12-IN-E9 is a potent and selective covalent CDK12 inhibitor and a non-covalent CDK9 inhibitor, while avoiding ABC transporter-mediated efflux. CDK12-IN-E9 has weak binding ability to CDK7/CyclinH complex with an IC50> 1 μM. | ||
| M29171 | CDK2-IN-4 | CDK |
| CDK2-IN-4 is a potent and selective CDK2 inhibitor with an IC50 of 44 nM for CDK2/cyclin A, shows 2,000-fold selectivity over CDK1/cyclin B (IC50=86 uM). | ||
| M29353 | CDK1-IN-2 | CDK |
| CDK1-IN-2 is a CDK1 inhibitor (IC50: 5.8 μM). | ||
| M29364 | CDK12-IN-3 | CDK |
| CDK12-IN-3 is a potent and selective CDK12 inhibitor with an IC50 of 491 nM in enzymatic assay. | ||
| M30104 | Cdk1/2 Inhibitor III | CDK |
| Cdk1/2 Inhibitor III is a selective Cdk1/2 inhibitor, with an IC50 of 2.1 μM for CDK1/cyclin B. | ||
| M31195 | CDK1/2/4-IN-1 | CDK |
| CDK1/2/4-IN-1 is a potent CDK inhibitor with IC50 values of 1.47, 0.78 and 0.87 μM for CDK1, CDK2 and CDK4, respectively. CDK1/2/4-IN-1 arrests cell cycle at G2/M phase and induces apoptosis. CDK1/2/4-IN-1 elevates Bax, caspase-3, P53 levels and decreases Bcl-2 level. | ||
| M31196 | CDK12-IN-2 | CDK |
| CDK12-IN-2 is a potent, selective and nanomolar CDK12 inhibitor (IC50=52 nM). CDK12-IN-2 is also a strong CDK13 inhibitor due to CDK13 is the closest homologue of CDK12. CDK12-IN-2 inhibits the phosphorylation of Ser2 in the C-terminal domain of RNA polymerase II. CDK12-IN-2 can be used an excellent chemical probe for functional studies of CDK12. | ||
| M31197 | CDK2/4/6-IN-1 | CDK |
| CDK2/4/6-IN-1 is a CDK2/4/6 inhibitor with IC50 values of 2.5, 23.7 and 44.3 nM for CDK2, CDK4 and CDK6, respectively. CDK2/4/6-IN-1 can be used in cancer research. | ||
| M31199 | CDK-IN-2 | CDK |
| CDK-IN-2 is a potent and specific CDK9 inhibitor with IC50 of <8 nM. | ||
| M31276 | PROTAC CDK2/9 Degrader-1 | PROTAC |
| PROTAC CDK2/9 Degrader-1 is a potent dual degrader for CDK2 (DC50=62 nM) and CDK9 (DC50=33 nM). PROTAC CDK2/9 Degrader-1 suppresses prostate cancer PC-3 cell proliferation (IC50=0.12 µM) by effectively blocking the cell cycle in S and G2/M phases. PROTAC CDK2/9 Degrader-1 is a PROTAC by tethering CDK inhibitor with Cereblon ligand. | ||
| M41425 | CDK7-IN-25 | CDK |
| CDK7-IN-25 (CY-16-1) is a CDK-7 inhibitor (IC50<1nM) that can be used in cancer research. | ||
| M41430 | CDK2-IN-19 | CDK |
| CDK2-IN-19 is a selective and orally active CDK2 inhibitor (Ki: 0.18 nM). | ||
| M41431 | CDK4-IN-2 | CDK |
| CDK4-IN-2 is a CDK4 inhibitor, with Ki and IC50 values of <10 nM. | ||
| M41435 | CDK9-IN-23 | CDK |
| CDK9-IN-23 is a CDK9 inhibitor with an IC50 of <20 nM. | ||
| M41436 | CDK2/Bcl2-IN-1 | CDK |
| CDK2/Bcl2-IN-1 with promising cytotoxicity against cancer cells. | ||
| M41438 | CDK2-IN-15 | CDK |
| CDK2-IN-15 is an inhibitor of CDK2 with an IC50 of 2.9 μM. | ||
| M41439 | CDK7-IN-22 | CDK |
| CDK7-IN-22 is an CDK7 inhibitor with antitumor activity. | ||
| M41441 | CDK9-IN-27 | CDK |
| CDK9-IN-27 is a CDK9 inhibitor (IC50s: 0.424 μM). | ||
| M41442 | CDK9-IN-26 | CDK |
| CDK9-IN-26 is a CDK9 inhibitor (IC50=0.18 μM). | ||
| M41443 | CDK-IN-12 | CDK |
| CDK-IN-12 is a CDK Inhibitor. | ||
| M41444 | CDK7-IN-21 | CDK |
| CDK7-IN-21 is a potent CDK7 inhibitor. | ||
| M43430 | PROTAC CDK12/13 Degrader-1 TFA | PROTAC |
| PROTAC CDK12/13 Degrader-1 TFA is a highly selective cell cycle protein-dependent kinase CDK12/CDK13 dual degrader with the DC50 values of 2.2 nM and 2.1 nM, respectively. | ||
| M49512 | CDK7-IN-20 | CDK |
| CDK7-IN-20 is a potent, selective and irreversible CDK7 (CDK) inhibitor with an IC50 value of 4 nM. | ||
| M49513 | CDK8-IN-12 | CDK |
| CDK8-IN-12 is an orally active, potent CDK8 inhibitor with a Ki of 14 nM. | ||
| M49514 | GSK-3/CDK5/CDK2-IN-1 | CDK |
| GSK-3/CDK5/CDK2-IN-1, an imidazole derivative, is an inhibitor of cdk5, cdk2, and GSK-3 extracted from patent WO2002010141A1, example 9a. | ||
| M53360 | Cdk2/Cyclin Inhibitory Peptide I | CDK |
| Cdk2/Cyclin Inhibitory Peptide I (Tat-LFG), a CDK2 inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
